109 related articles for article (PubMed ID: 12878365)
1. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
Shargorodsky M; Wainstein J; Gavish D; Leibovitz E; Matas Z; Zimlichman R
Am J Hypertens; 2003 Aug; 16(8):617-22. PubMed ID: 12878365
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Yosefy C; Magen E; Kiselevich A; Priluk R; London D; Volchek L; Viskoper RJ
J Cardiovasc Pharmacol; 2004 Aug; 44(2):215-22. PubMed ID: 15243303
[TBL] [Abstract][Full Text] [Related]
5. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Regensteiner JG; Bauer TA; Reusch JE
Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone.
Garg R; Gopal J; Jones GR
J Diabetes Complications; 2007; 21(1):1-6. PubMed ID: 17189867
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Phillips JW; Barringhaus KG; Sanders JM; Yang Z; Chen M; Hesselbacher S; Czarnik AC; Ley K; Nadler J; Sarembock IJ
Circulation; 2003 Oct; 108(16):1994-9. PubMed ID: 14517165
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
12. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Pistrosch F; Passauer J; Fischer S; Fuecker K; Hanefeld M; Gross P
Diabetes Care; 2004 Feb; 27(2):484-90. PubMed ID: 14747233
[TBL] [Abstract][Full Text] [Related]
13. Circulating ApoJ is closely associated with insulin resistance in human subjects.
Seo JA; Kang MC; Ciaraldi TP; Kim SS; Park KS; Choe C; Hwang WM; Lim DM; Farr O; Mantzoros C; Henry RR; Kim YB
Metabolism; 2018 Jan; 78():155-166. PubMed ID: 28986164
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
[TBL] [Abstract][Full Text] [Related]
15. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
Sarafidis PA; Lasaridis AN; Nilsson PM; Hitoglou-Makedou AD; Pagkalos EM; Yovos JG; Pliakos CI; Tourkantonis AA
Am J Hypertens; 2005 Feb; 18(2 Pt 1):227-34. PubMed ID: 15752951
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
17. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.
Türkmen Kemal Y; Güvener Demirag N; Yildirir A; Atar A; Dogruk Unal A; Biyiklioglu Z
Acta Diabetol; 2007 Sep; 44(3):149-56. PubMed ID: 17721754
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
[TBL] [Abstract][Full Text] [Related]
20. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes.
Kulenović I
Med Arh; 2006; 60(3):179-81. PubMed ID: 16719233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
